TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comfort Level of Two Abdominal Compression Methods Used to Hold Patients Still While Undergoing Stereotactic Body Radiation Therapy for Lung Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* All lung patients from the University of Texas Southwestern Medical Center, Parkland Health and Hospital System, and Richardson Regional Cancer Center scheduled to receive stereotactic body radiotherapy simulation~* Must have initial pre-compression lung tumor motions with respiration \> 1 cm~PATIENT CHARACTERISTICS:~* Negative pregnancy test~PRIOR CONCURRENT THERAPY:~* Concurrent participation in other protocols allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Treatment Efficacy of a Modified Positive Airway Pressure Device to Treat Obstructive Sleep Apnea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 and over~* Diagnosed with OSA by a practicing physician and prescribed Positive Airway Pressure (PAP) - (Continuous Positive Airway Pressure (CPAP) or AutoCPAP). Participants can be naïve to CPAP or experienced users of CPAP.~* For experienced users of PAP (CPAP or AutoCPAP): Using the PAP of more than 4 hours/night for 70% during the last 30 days (justification allowed by the investigator)~Exclusion Criteria:~* Contraindicated for PAP (CPAP or AutoCPAP) therapy~* Persons with other significant sleep disorder(s) (e.g periodic leg movements, insomnia, central sleep apnea)~* Persons with obesity hypoventilation syndrome or congestive heart failure.~* Persons that require supplemental oxygen with their PAP (CPAP or AutoCPAP) device~* Persons with implanted electronic medical device (e.g cardiac pacemakers)~* Persons who are pregnant or think they might be pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FPH Device with SensAwake On + Pressure Support A (Type: ACTIVE_COMPARATOR): FPH Device with SensAwake On + Pressure Support A
- FPH Device with SensAwake Off + Pressure Support A (Type: ACTIVE_COMPARATOR): FPH Device with SensAwake Off + Pressure Support A
- FPH Device with SensAwake On + Pressure Support B (Type: ACTIVE_COMPARATOR): FPH Device with SensAwake On + Pressure Support B
- FPH Device with SensAwake Off + Pressure Support B (Type: ACTIVE_COMPARATOR): FPH Device with SensAwake Off + Pressure Support B
- Competitor's PAP Released Device + Pressure Support A (Type: ACTIVE_COMPARATOR): Competitor's PAP Released Device + Pressure Support A
- Competitor's PAP Released Device + Pressure Support B (Type: ACTIVE_COMPARATOR): Competitor's PAP Released Device + Pressure Support B

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Concomitant Application of TENS and NMES on Chronic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~First episode of unilateral stroke with hemiparesis Stroke confirmed by CT and/or MRI Ablity to independently stand up from a chair~Exclusion Criteria:~Cerebellar or brainstem stroke Severe cognitive and communication impairment Previous surgical treatment history on the affected extremity Complication with severe heart, lung, liver, kidney, or infectious disease Presence of a cardiac pacemaker Orthopedic disease affecting sit-to-stand movement Inability to understand and follow verbal commands Peripheral or central nervous system dysfunction

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- TENS+NMES Group (Type: EXPERIMENTAL): The group in which TENS and NMES are applied concomitantly in the treatment
- TENS Group (Type: ACTIVE_COMPARATOR): The group in which TENS is applied concomitantly in the treatment
- NMES Group (Type: ACTIVE_COMPARATOR): The group in which NMES is applied concomitantly in the treatment
- Control (Type: SHAM_COMPARATOR): No additional electrical stimulation is applied for treatment in this group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically or cytologically-confirmed, locally advanced, or metastatic solid malignancy that is relapsed, refractory, or progressing following at least 1 prior systemic therapy (Part A)~* Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) as defined by RECIST 1.1~* Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 1~* Patients in Part B must have histologically or cytologically-confirmed, locally-advanced, or metastatic solid malignancy within the disease indications of Part A~* Adequate baseline hematologic, renal, and hepatic function~* Patients for whom there is no further standard therapy available at the time of enrollment (Part A)~* Patients with a histologically-confirmed, advanced solid malignancy meeting one of the following criteria: (1) indication for which pembrolizumab is approved or (2) relapsed, refractory, or progressive disease following at least 1 prior therapy and for which no further standard therapy is a available (Parts C and D)~Exclusion Criteria:~* Patients with carcinomatous meningitis or active central nervous system (CNS) metastases~* Patients with recent (within 14 days) or serious ongoing infection~* Patients requiring systemic treatment with corticosteroids (greater than 10 mg prednisone equivalents) or immunosuppressive medications within 14 days of enrollment~* Patients with active known or suspected autoimmune disease or significant autoimmune-related toxicity from prior immuno-oncology therapy~* Known active or latent tuberculosis~* Uncontrolled diabetes mellitus~* History of interstitial lung disease~* Gastrointestinal abnormality that would affect absorption of SGN-2FF~* Patients tested positive for hepatitis B or with a known, active hepatitis C infection~* Women who are pregnant or breastfeeding~* Patients with deep vein thrombosis (DVT)~* Contraindication to prophylactic anticoagulation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SGN-2FF (Type: EXPERIMENTAL): Dose escalation and dose expansion
- SGN-2FF and Pembrolizumab (Type: EXPERIMENTAL): Dose escalation and dose expansion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* On thrice weekly chronic hemodialysis for at least 6 months~* Clinically stable, adequately dialyzed \[single-pool Kt/V \> 1.2 or Urea Reduction Ratio (URR) \> 65%\] thrice weekly, with polysulphone membrane for at least 3 consecutive months prior to study~Exclusion Criteria:~* History of functional transplant less than 6 months prior to study~* Use of immunosuppressive drugs within 1 month prior to study~* History of active connective tissue disease~* History of acute infectious disease within one month prior to study~* AIDS (HIV seropositivity is not an exclusion criteria)~* History of myocardial infarction or cerebrovascular event within 3 months~* Advanced liver disease~* Gastrointestinal dysfunction requiring parental nutrition~* Active malignancy excluding basal cell carcinoma of the skin~* History of ACE inhibitor-associated cough (intolerable) or angioedema~* Ejection fraction less than 30%~* Inability to discontinue ACE inhibitor or ARB~* Predialysis potassium repeatedly higher than 6.0 mmol/L (confirmed on a repeated blood draw)~* Anticipated live donor kidney transplant~* Pregnancy or breast-feeding~* History of poor adherence to hemodialysis or medical regimen~* Inability to provide consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Valsartan (Type: ACTIVE_COMPARATOR): 80 mg of valsartan (ARB) taken orally on a daily basis for 1 week followed by 160 mg of valsartan taken orally on a daily basis for 18 months
- Ramipril (Type: ACTIVE_COMPARATOR): 2.5 mg of ramipril (ACE inhibitor) taken orally on a daily basis for 1 week followed by 5 mg of ramipril taken orally on a daily basis for 18 months
- Placebo (Type: PLACEBO_COMPARATOR): matching placebo taken orally on a daily basis for 1 week followed by matching placebo taken orally on a daily basis for 18 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Young Blind Child Melatonin Treatment Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 1-20 years~* Blindness for the past year (verified by an ophthalmologic exam), but otherwise in general good health.~Exclusion Criteria:~* Abnormal heart, lung, kidney, liver disease or a primary sleep disorder,~* Significant clinical abnormalities (other than blindness),~* Use of medications with known effects on melatonin metabolism (e.g. beta-adrenergic blocking drugs or tricyclic antidepressants).

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- Melatonin (Type: EXPERIMENTAL): Subjects may opt to enroll in this treatment sub-study involving melatonin treatment (0.1 - 3 mg, daily) for up to 1 year, with a minimum of 6 weeks. Throughout treatment, subjects will continue their saliva, plasma, and/or urine sampling to test for treatment efficacy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients with Type 2 Diabetes who are:~* Prescribed Forxiga for glycaemic management AND~* Who have the ability to provide informed consent~Exclusion Criteria:~Patients with whom use of Forxiga is contraindicated:~* Patients with Type 1 Diabetes~* Patients with moderate to severe renal impairment \[Creatinine clearance (CrCl) \<60 mL/min or estimated glomerular filtration rate (eGFR) \<60mL/min/1.73m²\]~Additional exclusion criteria:~* Age \>75 years~* Concomitant use of loop diuretics or pioglitazone~* Patients who are currently on another SGLT2 inhibitor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- T2DM patients newly prescribed Forxiga (Type: None): A post-marketing evaluation of the safety of Forxiga (10 mg tablets, orally once daily for 6 months) through an observational prescription adverse event monitoring program (registry-based monitoring program) is warranted to assess real-world incidence of adverse events in routine clinical practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Motor Control Mechanisms in DBS-implanted Parkinson's Disease Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* PD patients that are monitored for the tuning of their DBS stimulator by Grenoble's Hospital.~* PD patients that are hospitalized for the tuning routine 12 months after the surgical implantation.~* Good tolerance following temporary stops of the DBS stimulator~* Affiliated to a social security system~* Mental abilities sufficient for performing the behavioral tasks (MMSE score \>= 24, tested less than 6 months ago)~Exclusion Criteria:~* Patients that are concerned by articles L1121-5, L1121-6, L1121-7 and L1121-8 of French Code de la Santé Publique,~* History of psychiatric or neurological illness other than PD~* Patients that are currently excluded from an other clinical trial~* Contraindications for TMS practice~* Inability to stay seated without pain for two hours~* Pregnancy

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Deep brain stimulation ON (Type: ACTIVE_COMPARATOR): Patients will undergo every experimental tasks with their DBS stimulator in ON and OFF positions. Order of ON/OFF conditions will be counterbalanced between patients.
- Deep brain stimulation OFF (Type: PLACEBO_COMPARATOR): Patients will undergo every experimental tasks with their DBS stimulator in ON and OFF positions. Order of ON/OFF conditions will be counterbalanced between patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dynamic Evaluation of Ankle Joint and Muscle Mechanics in Children With Spastic Equinus Deformity Due to Cerebral Palsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Equinus cohort inclusion criteria:~* children between 7 and 14 years old~* with unilateral CP and GMFCS score of I or II~* with the presence of fixed equinus defined as a fixed limitation of dorsiflexion inferior to 0°~Control cohort inclusion criteria:~* age and gender matched to equinus cohort~* no history of lower limb musculo-skeletal injury in past 6 months~* no history of lower limb musculoskeletal surgery in past six months~* no contraindications to MRI~Equinus cohort exclusion criteria:~* history of lower limb musculo-skeletal surgery~* botulinum toxin injection in past 6 months~* contraindications to MRI~* Uncooperative patient who refused to sign the informed consent~* Patient unable to understand the protocol, under guardianship~* Patients not affiliated to the Social Security.~Control cohort exclusion criteria:~* Uncooperative patient who refused to sign the informed consent~* Patient unable to understand the protocol, under guardianship~* Patients not affiliated to the Social Security.

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 14 Years
- Healthy Volunteers: t

Study Arms:
- Equinus cohort (Type: EXPERIMENTAL): 15 childrens who have a fixed equinus defined as a fixed limitation of dorsiflexion inferior to 0°.~Interventions: MRI scanner and gait analysis
- Control cohort (Type: EXPERIMENTAL): In this cohort, there will be 15 childrens with age and gender matched to equinus cohort and with no history of lower limb musculo-skeletal injury in past 6 months.~Interventions: MRI scanner and gait analysis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Trial of TPF Induction Chemotherapy in cN2 OSCC Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18 to 75 years old.~* Sex: both males and females.~* Karnofsky performance status (KPS) \>60.~* Histological biopsy confirming squamous cell carcinoma of the oral cavity (tongue, gingiva, buccal mucosa, floor of mouth, palate, and retromolar region).~* Clinical stage III/IVA (T1-2, N2, M0 or T3-4, N2, M0, UICC\[International Union Against Cancer \]2002) with resectable lesions.~* Adequate hematologic function: white blood cell \>3,000/mm3, hemoglobin\>8g/L, platelet count\>80,000/mm3.~* Hepatic function: ALAT(alanine aminotransferase )/ASAT(aspartate transaminase ) \<2.5 times the upper limit of normal (ULN), bilirubin \<1.5 times ULN.~* Renal function: serum creatinine \<1.5 times ULN.~* Written informed consent~Exclusion Criteria:~* Evidence of distant metastatic disease and other cancers.~* Surgical procedure of the primary tumors or lymph nodes (except diagnostic biopsy).~* Previous radiotherapy or chemotherapy.~* Other previous malignancies within 5 years.~* Can not tolerate the treatment protocol with systematic diseases such as history of severe pulmonary or cardiac diseases.~* Legal incapacity or limited legal capacity.~* Creatinine clearance \<30ml/min.~* Pregnancy (confirmed by serum or urine β-HCG) or lactation period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- TPF group (Type: EXPERIMENTAL): The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed with surgery and radiotherapy/chemoradiotherapy.~docetaxel:75mg/m2 cisplatin：75 mg/m2 5-Fu：750 mg/m2/day
- Control group (Type: OTHER): The patients in the control group received the radical surgery and radiotherapy/chemoradiotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PERFORM = Pentaglobin® Registry For Outcome Report and Monitoring

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Age ≥ 18 years~* Diagnosis of severe bacterial infection~* Pentaglobin® use~* signed informed consent for data collection -~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologic evidence of NASH upon central read of a liver biopsy obtained no more than 6 months before Day 1 defined by presence of all 3 key histological features of NASH according to NASH CRN criteria.~2. Histologic evidence of fibrosis stage 2 or stage 3 as defined by the NASH CRN scoring of fibrosis, or~   Histologic evidence of fibrosis stage 1a or stage 1b if accompanied by ≥1 of the following risk factors:~  * Obesity (BMI ≥30 kg/m2)~  * Type 2 diabetes diagnosed per 2013 American Diabetes Association criteria~  * ALT \>1.5× upper limit of normal (ULN).~3. For subjects with a historical biopsy, is either not taking or is on stable doses of TZDs/glitazones or vitamin E for 6 months before Day 1.~4. Stable body weight.~Exclusion Criteria:~1. Model for End-stage Liver Disease (MELD) score \>12~2. ALT ≥10× ULN~3. HbA1c \>9.5%~4. Total bilirubin \>1.5 mg/dL~5. Evidence of other known forms of known chronic liver disease such as alcoholic liver disease, hepatitis B, hepatitis C, PBC, PSC, autoimmune hepatitis, Wilson disease, iron overload, alpha-1-antitrypsin deficiency, drug-induced liver injury, known or suspected hepatocellular carcinoma (HCC)~6. History of liver transplant, or current placement on a liver transplant list~7. Current or history of significant alcohol consumption~8. Prior or planned ileal resection, or prior or planned bariatric surgery~9. Histological presence of cirrhosis~10. History of biliary diversion~11. Known positivity for human immunodeficiency virus infection.~12. Acute cholecystitis or acute biliary obstruction.~13. BMI \>45 kg/m2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 10 mg Obeticholic Acid (Type: EXPERIMENTAL): 10 mg Obeticholic Acid daily for the remainder of the study
- 25 mg Obeticholic Acid (Type: EXPERIMENTAL): 25 mg Obeticholic Acid daily for the remainder of the study
- Placebo (Type: PLACEBO_COMPARATOR): One tablet daily for the remainder of the study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy